
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Outperforming stock! In past three years, the stock has provided 27.3% return compared to 10.7% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 11% is a good sign.
No major cons observed.
Valuation | |
|---|---|
| Market Cap | 15.42 kCr |
| Price/Earnings (Trailing) | 28.27 |
| Price/Sales (Trailing) | 3.02 |
| EV/EBITDA | 14.9 |
| Price/Free Cashflow | 46.92 |
| MarketCap/EBT | 21.41 |
| Enterprise Value | 16.45 kCr |
Fundamentals | |
|---|---|
| Revenue (TTM) | 5.11 kCr |
| Rev. Growth (Yr) | 21.1% |
| Earnings (TTM) | 545.48 Cr |
| Earnings Growth (Yr) | 27.7% |
Profitability | |
|---|---|
| Operating Margin | 14% |
| EBT Margin | 14% |
| Return on Equity | 13.7% |
| Return on Assets | 7.86% |
| Free Cashflow Yield | 2.13% |
Growth & Returns | |
|---|---|
| Price Change 1W | -2.5% |
| Price Change 1M | 6.7% |
| Price Change 6M | 10.1% |
| Price Change 1Y | 27% |
| 3Y Cumulative Return | 27.3% |
| 5Y Cumulative Return | 14.5% |
| 7Y Cumulative Return | 28% |
| 10Y Cumulative Return | 17.9% |
Cash Flow & Liquidity | |
|---|---|
| Cash Flow from Investing (TTM) | -691.29 Cr |
| Cash Flow from Operations (TTM) | 866.57 Cr |
| Cash Flow from Financing (TTM) | -92.51 Cr |
| Cash & Equivalents | 608.61 Cr |
| Free Cash Flow (TTM) | 294.87 Cr |
| Free Cash Flow/Share (TTM) | 12.15 |
Balance Sheet | |
|---|---|
| Total Assets | 6.94 kCr |
| Total Liabilities | 2.96 kCr |
| Shareholder Equity | 3.98 kCr |
| Current Assets | 3.09 kCr |
| Current Liabilities | 2.42 kCr |
| Net PPE | 2.61 kCr |
| Inventory | 1.49 kCr |
| Goodwill | 11.65 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.24 |
| Debt/Equity | 0.41 |
| Interest Coverage | 5.82 |
| Interest/Cashflow Ops | 9.67 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 1.5 |
| Dividend Yield | 0.27% |
| Shares Dilution (1Y) | 0.10% |
| Shares Dilution (3Y) | 0.30% |
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Past Returns: Outperforming stock! In past three years, the stock has provided 27.3% return compared to 10.7% by NIFTY 50.
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Profitability: Recent profitability of 11% is a good sign.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.27% |
| Dividend/Share (TTM) | 1.5 |
| Shares Dilution (1Y) | 0.10% |
| Earnings/Share (TTM) | 22.48 |
Financial Health | |
|---|---|
| Current Ratio | 1.28 |
| Debt/Equity | 0.41 |
Technical Indicators | |
|---|---|
| RSI (14d) | 69.7 |
| RSI (5d) | 55.75 |
| RSI (21d) | 62.33 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal | Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
Summary of Granules India's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Granules India ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| KRISHNA PRASAD CHIGURUPATI | 30.99% |
| LIFE INSURANCE CORPORATION OF INDIA | 5.22% |
| CHIGURUPATI UMA DEVI | 3.73% |
| SBI LIFE INSURANCE CO. LTD | 3.3% |
| KOTAK MAHINDRA LIFE INSURANCE COMPANY LTD. | 1.74% |
| TYCHE INVESTMENTS PRIVATE LIMITED | 1.43% |
| SMALLCAP WORLD FUND, INC | 1.39% |
| BASAVA SANKARA RAO KOLLI | 1.17% |
| 360 ONE PIPE FUND | 1.1% |
| PRAGNYA CHIGURUPATI | 0.74% |
| CHIGURUPATI PRIYANKA | 0.73% |
| SANTHI SREE RAMANAVARAPU | 0.35% |
| SUSEELA DEVI CHIGURUPATI | 0.03% |
| NIKHILA REDDY YEDAGURI | 0.01% |
| HARSHA CHIGURUPATI | 0% |
| KALIDINDI ABINAV VARMA | 0% |
| VENKATA MAHESH KRISHNA NARRA | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
Detailed comparison of Granules India against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 3.97 LCr | 58.94 kCr | -9.40% | +0.20% | 36.37 | 6.74 | - | - |
| DIVISLAB | Divi's Lab | 1.62 LCr | 10.75 kCr | -3.70% | +13.60% | 65.55 | 15.11 | - | - |
| DRREDDY | Dr. Reddy's Lab | 1.03 LCr | 36.09 kCr | -7.30% | +12.30% | 18.38 | 2.84 | - | - |
| CIPLA | Cipla | 99.34 kCr | 29.37 kCr | -7.50% | -13.10% | 21.84 | 3.38 | - | - |
| AUROPHARMA | Aurobindo Pharma | 78.54 kCr | 33.73 kCr | +3.60% | +27.80% | 22.52 | 2.33 | - | - |
Comprehensive comparison against sector averages
GRANULES metrics compared to Pharmaceuticals
| Category | GRANULES | Pharmaceuticals |
|---|---|---|
| PE | 28.27 | 33.70 |
| PS | 3.02 | 4.65 |
| Growth | 14.2 % | 8 % |
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
GRANULES vs Pharmaceuticals (2021 - 2026)